Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

Summary

This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.

Timeline

Start

2022-04-06

Primary completion

2023-11-07

Completion

2023-11-07

Drugs

Indications